Related references
Note: Only part of the references are listed.The prognostic impact of hexaminolevulinate-based bladder tumor resection in patients with primary non-muscle invasive bladder cancer treated with radical cystectomy
Markus Renninger et al.
WORLD JOURNAL OF UROLOGY (2020)
Cost-effectiveness analysis of blue light cystoscopy with hexylaminolevulinate in transurethral resection of the bladder
G. Gakis et al.
UROLOGE (2019)
Cost-effectiveness analysis of blue light cystoscopy with hexylaminolevulinate in transurethral resection of the bladder
G. Gakis et al.
UROLOGE (2019)
Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study
Siamak Daneshmand et al.
JOURNAL OF UROLOGY (2018)
Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry
Siamak Daneshmand et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2018)
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
Marko Babjuk et al.
EUROPEAN UROLOGY (2017)
'Real-life experience': recurrence rate at 3 years with Hexvix® photodynamic diagnosis-assisted TURBT compared with good quality white light TURBT in new NMIBC-a prospective controlled study
Kevin M. Gallagher et al.
WORLD JOURNAL OF UROLOGY (2017)
Characteristics and external validity of the German Health Risk Institute (HRI) Database
Frank Andersohn et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2016)
Economic Burden of Bladder Cancer Across the European Union
Jose Leal et al.
EUROPEAN UROLOGY (2016)
Cost-effectiveness of transurethral resection of the bladder with blue light in patients with non muscle invasive bladder cancer in France
M. Roupret et al.
PROGRES EN UROLOGIE (2015)
Technical solutions to improve the management of non-muscle-invasive transitional cell carcinoma: summary of a European Association of Urology Section for Uro-Technology (ESUT) and Section for Uro-Oncology (ESOU) expert meeting and current and future perspectives
Thorsten Bach et al.
BJU INTERNATIONAL (2015)
Clinical and Cost Effectiveness of Hexaminolevulinate-guided Blue-light Cystoscopy: Evidence Review and Updated Expert Recommendations
J. Alfred Witjes et al.
EUROPEAN UROLOGY (2014)
Hexyl Aminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-up of Patients with Non-Muscle-invasive Bladder Cancer: A Critical Review of the Current Literature
Michael Rink et al.
EUROPEAN UROLOGY (2013)
Photodynamic Diagnosis of Non-muscle-invasive Bladder Cancer with Hexaminolevulinate Cystoscopy: A Meta-analysis of Detection and Recurrence Based on Raw Data
Maximilian Burger et al.
EUROPEAN UROLOGY (2013)
Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Bogdan Geavlete et al.
BJU INTERNATIONAL (2012)
Long-Term Decrease in Bladder Cancer Recurrence with Hexaminolevulinate Enabled Fluorescence Cystoscopy
H. Barton Grossman et al.
JOURNAL OF UROLOGY (2012)
Hexaminolevulinate Guided Fluorescence Cystoscopy Reduces Recurrence in Patients With Nonmuscle Invasive Bladder Cancer
Arnulf Stenzl et al.
JOURNAL OF UROLOGY (2010)
Economic aspects of bladder cancer: what are the benefits and costs?
K. D. Sievert et al.
WORLD JOURNAL OF UROLOGY (2009)
Hexyl aminolevulinate - In the detection of bladder cancer
JE Frampton et al.
DRUGS (2006)
Improved detection and treatment of bladder cancer using hexaminolevulinate imaging:: A prospective, phase III multicenter study
D Jocham et al.
JOURNAL OF UROLOGY (2005)
Share Paper
